Avadel Pharmaceuticals plc(AVDL)

Search documents
Avadel Pharmaceuticals to Join Russell 3000® Index
GlobeNewswire News Room· 2024-06-27 20:05
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. “We are proud to be included in the widely tracked Russ ...
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
globenewswire.com· 2024-05-22 12:00
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care – DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as a narcolepsy treatment option at SLEEP 2024, the 38th ...
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
Newsfilter· 2024-05-21 11:00
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. "On behalf of the entire Avadel team, we are excited to welcome Dr. Am ...
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
globenewswire.com· 2024-05-21 11:00
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. “On behalf of the entire Avadel team, we are excited to welcome Dr. A ...
Avadel Pharmaceuticals plc(AVDL) - 2024 Q1 - Earnings Call Transcript
2024-05-08 16:52
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Austin Murtagh - Director at Stern Investor Relations Gregory Divis - CEO Richard Kim - Chief Commercial Officer Thomas McHugh - CFO Conference Call Participants Andrew Tsai - Jefferies François Brisebois - Oppenheimer Ami Fadia - Needham & Company David Amsellem - Piper Sanger Marc Goodman - Leerink Partners Ashwani Verma - UBS Oren Livnat - H.C. Wainwright Chase Knickerbocker - Craig Hallu ...
Avadel Pharmaceuticals plc(AVDL) - 2024 Q1 - Quarterly Report
2024-05-08 13:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, nominal value $0.01 per share AVDL The Nasdaq Global Market FORM 10-Q ——————— ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ...
Avadel Pharmaceuticals plc(AVDL) - 2024 Q1 - Quarterly Results
2024-05-08 11:08
Revenue and Sales Performance - Generated $27.2 million in net revenue from sales of LUMRYZ for the quarter ended March 31, 2024[5] - More than 1,700 patients initiated therapy with LUMRYZ, representing an increase of over 70% from December 31, 2023[3] - Over 2,800 patients enrolled in Avadel's RYZUP patient support services, an increase of approximately 50% since December 31, 2023[3] Expenses and Financial Performance - R&D expenses decreased to $3.1 million for the quarter, down from $3.8 million in the same period in 2023[5] - SG&A expenses increased to $48.6 million, compared to $24.5 million for the same period in 2023, driven by higher commercial launch costs[5] - Net loss for the quarter was $27.3 million, or ($0.30) per diluted share, compared to a net loss of $30.8 million, or ($0.48) per diluted share, for the same period in 2023[6] - Net loss for the three months ended March 31, 2024, was $27,342,000, an improvement from a net loss of $30,784,000 for the same period in 2023, representing a reduction of 7.93%[27] - The company reported a significant increase in share-based compensation expense to $5,389,000 for the three months ended March 31, 2024, compared to $1,522,000 for the same period in 2023[27] Cash and Assets - Cash, cash equivalents, and marketable securities totaled $88.8 million as of March 31, 2024[6] - Cash and cash equivalents rose to $35,794,000 at March 31, 2024, up from $31,167,000 at December 31, 2023, marking an increase of 14.99%[26] - Total current assets increased to $136,035,000 as of March 31, 2024, compared to $134,202,000 at December 31, 2023, reflecting a growth of 1.36%[23] Liabilities and Equity - Total liabilities increased to $89,515,000 as of March 31, 2024, compared to $76,959,000 at December 31, 2023, indicating a rise of 16.31%[24] - Total shareholders' equity decreased to $78,384,000 as of March 31, 2024, down from $87,739,000 at December 31, 2023, reflecting a decline of 10.66%[25] Market and Regulatory Developments - The FDA accepted the sNDA for LUMRYZ for pediatric narcolepsy, with a target action date of September 7, 2024[4] - The company is on track to enroll the first patient in a Phase 3 pivotal trial for idiopathic hypersomnia in the second half of 2024[4] Cash Flow and Financing Activities - Proceeds from sales of marketable securities amounted to $119,066,000 for the three months ended March 31, 2024, significantly higher than $15,295,000 for the same period in 2023[27] - Net cash used in operating activities was $29,704,000 for the three months ended March 31, 2024, slightly better than $30,233,000 for the same period in 2023, showing a decrease of 1.75%[27] - Cash flows from financing activities provided $13,190,000 for the three months ended March 31, 2024, compared to $34,442,000 for the same period in 2023, showing a decrease of 61.73%[27] Operating Lease and Other Liabilities - The current portion of operating lease liability increased to $953,000 as of March 31, 2024, compared to $934,000 at December 31, 2023, indicating a rise of 2.04%[24]
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
Newsfilter· 2024-05-01 12:00
Company Update - Avadel Pharmaceuticals plc will host a conference call and live webcast on May 8, 2024, at 8:30 a.m. ET to provide a corporate update and discuss financial results for Q1 2024 [1] - Investors can access the conference call by dialing +1 (800) 715-9871 for U.S. and Canada or +1 (646) 307-1963 for international calls, using conference ID 2270373 [1] Product Information - Avadel's commercial product, LUMRYZ™, is the first and only once-at-bedtime oxybate approved by the FDA for treating cataplexy or excessive daytime sleepiness in adults with narcolepsy [2]
Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know
Zacks Investment Research· 2024-04-29 14:56
Core Viewpoint - Avadel (AVDL) shows potential for significant upside based on analysts' price targets, with a mean target of $22.90 indicating a 28.6% upside from the current price of $17.81 [1] Price Target Analysis - The average price target consists of 10 estimates ranging from $19 to $29, with a standard deviation of $3, indicating a relatively high agreement among analysts [1] - The lowest estimate suggests a 6.7% increase, while the highest points to a 62.8% upside [1] Analyst Sentiment - Analysts exhibit strong agreement on AVDL's earnings prospects, with a positive trend in earnings estimate revisions supporting the potential for stock price increases [2][5] - The Zacks Consensus Estimate for the current year has risen by 0.3% over the past month, with one estimate increasing and no negative revisions [5] Zacks Rank - AVDL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [5]
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Seeking Alpha· 2024-04-02 07:40
miniseriesThesis on AVDL: Maintaining a Buy Rating Q4 2023 Earnings and Commercial Performance of Lumryz We update readers based on FY 2023 earnings print and litigation update, where we carefully evaluated our thesis and decided to maintain our buy rating on AVDL (our latest analysis). Avadel Pharmaceuticals reported its Q4 2023 earnings, highlighting the commercial traction of Lumryz, its novel once-nightly formulation of sodium oxybate for narcolepsy. We believe the earnings are positive based on the ...